A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)
Completed · Phase 3 · NCT03607422
Conditions: Atopic Dermatitis
At a glance
- Research payments reported, 2025
- $82,793
- U.S. investigators named
- 17
- Sites paid
- 18
- Planned or actual enrollment
- 912
About the trial
- Sponsor
- AbbVie
- Tested
- Placebo for Upadacitinib (drug), Upadacitinib (drug)
- Dates
- Started 2018-07-27; completion 2025-11-11
- Results posted
- Yes
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
From ClinicalTrials.gov, last updated 2026-06-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $82,793 in research payments for this study in 2025 (34 payments).
Products named: Rinvoq
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- James Krell Dermatology · Birmingham, AL
- Scott M. Dinehart, M.D. Mohs Surgery · Little Rock, AR
- Anton L. Duke, MD Pediatrics · Little Rock, AR
- Jennifer Soung, M.D. Dermatology · Santa Ana, CA
- Paul W. Wallace, MD Dermatology · Beverly Hills, CA
- Lon D. Lynn, D.O. Family Medicine · Tampa, FL
- Brittany O. Newton, MD Family Medicine · Daytona Beach, FL
- Eduardo T. Weiss, MD Dermatology · Hollywood, FL
- Victoria Kuohung, MD Dermatology · Quincy, MA
- Osman C. Dokmeci, M.D Allergy & Immunology · Albuquerque, NM
- Neil J. Korman, MD Dermatology · Cleveland, OH
- Iftikhar Hussain, MD Allergy & Immunology · Tulsa, OK
- Lauren S. Campbell, M.D. Dermatology · Cypress, TX
- David R. Hensley, M.D. Dermatology · Arlington, TX
- Ross C. Radusky, M.D. Dermatology · Dallas, TX
- Sarah I. Smiley, D.O. Hospitalist · Austin, TX
- John M. Agaiby, MD Family Medicine · Kenosha, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of New Mexico $13,651
- Metroplex Dermatology $12,034
- Clinical Research of West Florida $10,591
- Arkansas Research Trials LLC $8,289
- Uh Cleveland Medical Center, OH $4,486
- Clinical Investigation Specialists $4,000
- Clinical Investigation Specialists Inc $4,000
- Vital Prospects Clinical Research $3,883
- Paul W Wallace $3,825
- Beacon Clinical Research $3,322
- Total Skin and Beauty Dermatology Center PC $3,112
- Skin Care Research LLC $2,733
- Velocity Clinical Research Inc $2,220
- Complete Health Research $2,141
- Dermatology Trial Associates $2,113
- Southern California Dermatology Inc $1,891
- Studies in Dermatology LLC $259
- Dermatology Treatment & Research Center $243
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.